Neoleukin Therapeutics CEO Donna Cochener (L) and Neurogene CEO Rachel McMinn
July 18, 2023 10:18 AM EDTUpdated 03:01 PM
Startups
Deals
Cell/Gene Tx

New York gene ther­a­py start­up Neu­ro­gene eyes $200M from Ne­oleukin Nas­daq swap

Kyle LaHucik

Senior Reporter

Ne­oleukin Ther­a­peu­tics has found its re­verse merg­er part­ner about four months af­ter putting up the for-sale sign, as the Seat­tle biotech gives way to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

2024's bio­phar­ma win­ners and losers; Ca­griSe­ma falls short; Mer­ck swings Chi­na GLP-1 deal; and more

A service from the Financial Times